No Detail Found!

Immunohistochemical expression of PD-L1 in non-small cell lung carcinoma

Author(s)
Muhammad Umair Khan Armed Institute of Pathology, NUMS,Rawalpindi-,Pakistan
Hafeez ud Din Armed Institute of Pathology, NUMS,Rawalpindi-,Pakistan
Wajahat Ahmed Khan Armed Institute of Pathology, NUMS,Rawalpindi-,Pakistan
Abstract
Background: Lung cancer is a leading cause of death related to cancer worldwide, surpassing the number of deaths caused by breast, colon and prostate cancers. Objective of the study was to determine the frequency immunohistochemical expression of PD-L1 in non-small cell lung carcinoma (NSCLC). It was a descriptive cross-sectional study, carried out at the Department of Histopathology, Armed Forces Institute of Pathology, Rawalpindi, from January 2020 to July 2021. Methods: We inducted total of 145 diagnosed cases of NSCLC irrespective of age, gender, histological grade and stage of carcinoma . Immunohistochemical staining of PD-L1 was done using Leica kit. Patients with no expression for PD-L1 were considered negative, whereas immunohistochemical expression of =1% is considered positive. PD-L1 statuses of all patients was determined. The data was analyzed by using SPSS version 25. Results: In our study age ranges from 31 to 85 years with mean age of 64.20±10.90 years. Out of the 145 patients, 126 (86.90%) were male and 19 (13.10%) were females. 108 (74.50%) were squamous cell carcinoma and 37 (25.50%) were adenocarcinoma. Most of them were histological grade II, 88 (60.70%), followed by grade I in 26 (17.9%). Immunohistochemical expression of PD-Ll in NSCLC was found in 35 (24.13%) patients. Of all the positive cases, PD-L1 expression was slightly higher in adenocarcinoma 27.02% as compared to squamous cell carcinoma 23.14%. Conclusion: PD-L1 expression is associated with increased aggressiveness, enhanced tumor progression and shorter survival in patients of NSCLC. This study concluded that frequency of positive immunohistochemical expression of PD-L1 in NSCLC is though low, yet significant in adenocarcinoma as compared to squamous cell carcinoma.
Publication Details
Page(s) 611-615
Published Journal: Journal of Ayub Medical College, Volume: 36, Issue: 3, Year: 2024

Request the full text from PASTIC

Keywords
Programmed death 1, Non-small cell lung carcinoma (NSCLC), Programmed death ligand 1
References
Cruz CSD,Tanoue LT,Matthay RA .2011 .Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med, 32(4) : 605-44.
Glatzel-Plucinska N,Piotrowska A,Grzegrzolka J,Olbromski M,Rzechonek A,Dziegiel P .2018 .SATB1 level correlates with Ki-67 expression and is a positive prognostic factor in non-small cell lung carcinoma. Anticancer Res, 38(2) : 723-36.
Kanitkar AA,Schwartz AG,George J,Soubani AO .2018 .Causes of death in long-term survivors of non-small cell lung cancer: A regional Surveillance, Epidemiology, and End Results study. Ann Thorac Med, 13(2) : 76-81.
Konishi J,Yamazaki K,Azuma M,Kinoshita I,Dosaka-Akita H,Nishimura M. .2004 .B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res, 10(15) : 5094-100.
Sheppard KA,Fitz LJ,Lee JM,Benander C,George JA,Wooters J .2004 .PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3ζ signalosome and downstream signaling to PKCθ. FEBS Lett, 574(1- 3) : 37-41.
Parra ER,Villalobos P,Mino B,Rodriguez-Canales J .2018 .Comparison of different antibody clones for immunohistochemistry detection of programmed cell death ligand 1 (PD-L1) on non-small cell lung carcinoma. Appl Immunohistochem Mol Morphol, 26(2) : 83-93.
Pardoll DM .2012 .The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer, 12(4) : 252-64.
Ribas A,Tumeh PC .2014 .The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockade. Clin Cancer Res, 20(19) : 4982-4.
Mery CM,Pappas AN,Bueno R,Colson YL,Linden P,Sugarbaker DJ .2005 .Similar long-term survival of elderly patients with non-small cell lung cancer treated with lobectomy or wedge resection within the surveillance, epidemiology, and end results database. Chest, 128(1) : 237-45.
Ribas A,Hu-Lieskovan S A .2016 .What does PD-L1 positive or negative mean. J Exp Med, 213(13) : 2835-40.
Ghosh C,Luong G,Sun Y. .2021 .A snapshot of the PD-1/PD-L1 pathway. J Cancer, 12(9) : 2735-46.
Chen YY,Wang LB,Zhu HL,Li XY,Zhu YP,Yin YL .2013 .Relationship between programmed death-ligand 1 and clinicopathological characteristics in non-small cell lung cancer patients. Chin Med Sci J, 28(3) : 147-51.
Milovanovic IS,Stjepanovic M,Mitrovic D .2017 .Distribution patterns of the metastases of the lung carcinoma in relation to histological type of the primary tumor: an autopsy study. Ann Thorac Med, 12(3) : 191-8.
Chang YL,Yang CY,Huang YL,Wu CT,Yang PC .2017 .High PDL1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers. Oncotarget, 8(11) : 18021-30.
Devesa SS,Bray F,Vizcaino AP,Parkin DM .2005 .International lung cancer trends by histologic type: male: female differences diminishing and adenocarcinoma rates rising. Int J Cancer, 117(2) : 294-9.
Ma J,Chi D,Wang Y,Yan Y,Zhao S,Liu H .2018 .Prognostic value of PD-L1 expression in resected lung adenocarcinoma and potential molecular mechanisms. J Cancer, 9(19) : 3489-99.
Lin SY,Yang CY,Liao BC,Ho CC,Liao WY,Chen KY .2018 .Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: real-world data in Taiwan. J Cancer, 9(10) : 1813-20.
Igarashi T,Teramoto K,Ishida M,Hanaoka J,Daigo Y. .2016 .Scoring of PD-L1 expression intensity on pulmonary adenocarcinomas and the correlations with clinicopathological factors. ESMO Open, 1(4) : e000083.
Zhang M,Li G,Wang Y,Wang Y,Zhao S,Haihong P .2017 .PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis. Sci Rep, 7(1) : 10255.
Miyazawa T,Marushima H,Saji H,Kojima K,Hoshikawa M,Takagi M .2019 .PD-L1 expression in non-small-cell lung cancer including various adenocarcinoma subtypes. Ann Thorac Cardiovasc Surg, 25(1) : 1-9.
Cooper WA,Tran T,Vilain RE,Madore J,Selinger CI,Kohonen-Corish M .2015 .PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer, 89(2) : 181-8.
Scheel AH,Ansén S,Schultheis AM,Scheffler M,Fischer RN,Michels S .2016 .PD-L1 expression in non-small cell lung cancer: correlations with genetic alterations. Oncoimmunology, 5(5) : e1131379.
Lin G,Fan X,Zhu W,Huang C,Zhuang W,Xu H .2017 .Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer. Oncotarget, 8(48) : 83986-94.
Remmele W,Stegner H .1987 .Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe, 8(3) : 138-40.
Takada K,Okamoto T,Shoji F,Shimokawa M,Akamine T,Takamori S .2016 .Clinical significance of PD-L1 protein expression in surgically resected primary lung adenocarcinoma. J Thorac Oncol, 11(11) : 1879-90.
0

Citations

0

Downloads

35

Views